Management
Jeffrey T. Holt, MD, Founder, Chief Science Officer
Dr. Holt has been researching Breast and Ovarian Cancer for more than 25 years including being a part of the team of researchers that identified the function of the 2 breast cancer genes, BRCA1 and BRCA2. Jeff has expertise in pathology testing, tissue genetics, clinical trials, BRCA1 and BRCA2 research, regulatory experience, and biologics manufacturing. Jeff is a board-certified pathologist who completed post-doctoral studies in molecular genetics at NIH in 1987. Dr. Holt was the first to report a function for the BRCA1 breast cancer gene and has 4 patents on therapeutic applications of BRCA1 and BRCA2 function. Dr. Holt is currently the Professor of Pathology at The Commonwealth Medical College in Scranton, Pennsylvania.
Kimberly A. Gibson, Founder, Chief Executive Officer
Ms. Gibson has been working with Dr. Holt since 2001. Ms. Gibson has broad experiences in both industry and education from which she has gleaned her abilities in both management and science. She attended nursing school and then went on to earn a BS in Physical Science and Health Education from Central Michigan University. Kim has started and successfully operated three business ventures. Ms. Gibson was instrumental in co-founding and launching Tissue Genetics, including securing federal grant funding.
Medical Advisory Group
Henry T. Lynch, M.D.
Chairman, Dept. Preventive Medicine
President, Hereditary Cancer Center
Professor of Medicine, Creighton University
Brad Brimhall, M.D.
Chief Medical Officer, TriCore Laboratories
Clinical Associate Professor, Pathology, University of New Mexico School of Medicine
Roy A. Jenson, M.D.
Director, University of Kansas Cancer Center
Kenneth R. Shroyer, MD, PhD
Chair of Pathology Dept.
Stony Brook University Medical Center
State University of New York at Stony Brook
David L. Page, M.D.
Professor of Pathology and Preventive Medicine
Vanderbilt University Medical Center
